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ABSTRACT 
Since 2010, pharmaceutical organisations have begun to provide 
drug patents in sub-Saharan Africa through the UN Medicine Patent 
Pool. This initiative allows any pharmaceutical manufacturer to 
access these patents and manufacture the drugs, thereby aiming to 
decrease the associated lead times and costs. The participation of 
numerous manufacturers, some of whom may not have well-
established quality control systems in the market, intensifies the 
need for effective drug quality monitoring. Research indicates that 
it is often the case that these ‘niche drug provision systems’ face 
many challenges with the quality of new-generation drugs and the 
implementation of effective pharmacovigilance (PV)1 systems for 
the reporting of adverse drug reactions. The lack of resource 
efficiency in adverse drug reaction reporting within the sub-Saharan 
context is also a growing concern. 
OPSOMMING 
Sedert 2010 het farmaseutiese organisasies deur middel van die UN 
Medicine Patent Pool medisyne patente vrygestel vir lae- en 
middelinkomste lande. Hierdie inisiatief laat toe dat enige 
farmaseutiese vervaardiger die patente kan gebruik om medisyne te 
vervaardig; sodoende word die koste en vervaardigingstyd 
verminder. Aangesien ’n aantal verskillende vervaardigers, waarvan 
sommiges nie goed gevestigde kwaliteit stelsels het nie, kan 
deelneem, moet daar goeie ‘pharmacovigilance’ (PV) toegepas 
word. Navorsing dui egter daarop dat dit dikwels die geval is dat 
hierdie plaaslike medisyne vervaardigers baie uitdagings ervaar in 
verband met medisyne voorsiening wat weer effektiewe PV-stelsels 
impliseer. Die gebrek aan menslike hulpbronne vir die monitering 
van negatiewe reaksies op die medisyne in hierdie lande is ook ’n 
groeiende probleem.
 
1 INTRODUCTION 
In the contemporary landscape it is evident that there has been a significant shift in health care 
trends around the world that calls for innovative drug manufacturing, distribution, and surveillance 
monitoring. According to Rohrbach [1], the growing demand for healthcare  — combined with the 
switch in focus from treatment to prevention — has placed pharmaceutical companies under pressure 
from governments and consumers to reduce their prices and improve the value of their therapies. 
However, other stakeholders, such as the World Health Organization, also contribute to this 
pressure. The epidemic of communicable diseases in low- and middle-income countries adds to the 
pressure that pharmaceutical companies experience from stakeholders to ensure an affordable drug 
supply. According to the World Health Organization, in 2016 36.7 million people were living with 
                                                     
1  In this article, ‘PV’ means ‘pharmacovigilance’ which refers to the science and application of the 
detection, assessment, and monitoring of adverse drug reactions after drugs have been licensed for use. 
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HIV/AIDS, the majority of whom lived in low-middle income countries [2]. These factors, combined 
with strict drug patent laws, make the affordable supply of drugs in these countries problematic [3]. 
 
Thus in 2010 the UNITAID medicine patent pool (MPP)2 was established to improve access to the 
treatment of HIV, tuberculosis (TB), and hepatitis C by allowing access to specific drug patents [4], 
[5]. This innovation has played a significant role in addressing the HIV/AIDS epidemic from the 
perspective of access to medicine, as between 2005 and 2016 the proportion of patients receiving 
treatment increased from 6.9% to 53% globally [2]. However, the MPP has given rise to other 
challenges [6]. As multiple drug manufactures are allowed to access the drug patents, quality 
monitoring in these settings has to be very well-established. Such challenges are often attributed to 
inadequate local drug manufacturing and distribution systems [6]. 
 
However, when aiming to address specific challenges brought about by an intervention, as is the 
case with those arising from the MPP allowing any drug manufacturers access to patents, the context 
within which such a system exists has also to be considered. As mentioned earlier, the MPP only 
allows access to patents in low- and middle-income countries, which often have only limited 
resources. One example of limited resources in the sub-Saharan African region is the deficit of 24.8 
million doctors and nurses, resulting in 2.3 healthcare workers per 1000 people in Africa. This is 90% 
less than in the United States of America, where there are 24.8 healthcare workers per 1000 people 
[7]. In addition to the limited human resources in these countries, funding and opportunities for 
research and development are also limited [8]. Thus, when considering the challenges that arise 
through the implementation of the MPP, the context of limited resources should also be considered. 
 
These challenges in drug manufacturing and distribution in the context of resource-limited settings 
call for an effective, well-established drug monitoring and pharmacovigilance (PV)3 system to assist 
in improving patient safety. In order to develop such a PV system that will support, facilitate, and 
improve additional challenges brought on by inadequate drug manufacturing and distribution, the 
challenges need to be identified and understood to ensure that such a PV system overcomes them 
and does not give rise to any additional ones. It is also recognised that the current PV systems do 
not adequately support the unique MPP practices. This highlights the need for a PV system to support 
the unique needs of drug monitoring in such a setting, and to provide evidence that warrants the 
deployment of a PV system to support effective drug monitoring. In order to develop the 
characteristics of such a ‘niche PV system’4, a requirement specification will have to be developed. 
This requirement specification will be based partly on the insights gained from evaluating the 
challenges and incorporating best practices, current PV requirements, and the ability of the PV 
system to function in such a setting. A niche PV system can then be designed either by transforming 
the traditional PV system or by transitioning to a new PV system using the developed requirement 
specification. 
 
This paper, however, will focus on the challenges posed by drug manufacturing and distribution 
systems within resource-limited settings, which will be incorporated into the requirement 
specification for PV systems for such a setting. These challenges will be identified by conducting a 
systematic review, after which they will be arranged into a challenges landscape to understand the 
system perspective. Due to the high prevalence of HIV in South Africa, this research inquiry will 
consider challenges that arise with the roll-out of antiretrovirals (ARVs) [2].  
2 CONTEXTUALISATION: MPP DRUG SAFETY, MANUFACTURING, AND DISTRIBUTION IN 
RESOURCE-LIMITED SETTINGS 
Due to the growing number of HIV/AIDS patients without treatment in low- and middle-income 
countries, it was evident that an innovative way to provide antiretroviral treatment (ART) had to be 
                                                     
2  MPP is an initiative which allows any manufacturer to access the available patents and manufacture drugs; 
thereby aiming to decreasing lead time and costs associated with these drugs. 
3  ‘Pharmacovigilance’ is defined as the science and application of the detection, assessment, and monitoring 
of adverse drug reactions after drugs have been licensed for use.  
4  In this research inquiry, ‘niche PV system’ refers to a PV system that is designed for a specific population, 
implying a specific region and a specific drug. Such a PV system will most likely operate and be managed 
differently from ‘traditional’ PV systems. 
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implemented [2], [3]. One of the reasons that very few HIV/AIDS patients did not receive treatment 
was the high prices for treatment caused by the patent system, in which a company had the 
monopoly over a particular drug. ARVs also have to be taken in combination with other drugs, each 
with their own patent; and this also resulted in very high prices [3].  
 
Thus, in 2010 the MPP was established by UNITAID to increase access to treatments for specific 
communicable diseases such as HIV, hepatitis C, and TB in low- and middle-income countries through 
sharing technologies and patents [4]. A patent pool is defined as a collaboration between patent 
holders and other third parties, where licences are offered for use in exchange for a fixed price or 
royalties. The implementation of a medicine patent pool makes the production and distribution of 
drugs accessible to a broader population at a faster rate and at more affordable prices [3]. The WHO 
assist the MPP by prioritising the medicines that were required, and patent holders voluntarily 
agreed to license their medicines to the MPP, which in turn issued generic pharmaceutical companies 
with licence rights to manufacture these medicines.  
 
The implementation of MPP has many advantages, such as facilitating competition, improving low-
cost manufacturing, and encouraging research and development (R&D) [3], [9]–[11]. Through the 
implementation of the MPP, competition is facilitated because multiple drug manufacturing 
companies can access the same patents. As competition between manufacturers increases, drug 
prices drop, making drugs more affordable [9]. Through the MPP, low-cost manufacturing companies 
are also able to approach the patent pool to negotiate licensing agreements to create generic 
versions of these drugs [3]. As mentioned earlier, antiretroviral drugs need to be taken in 
combination with other drugs in order to be effective [3]. However, the patent pool encourages R&D 
and innovation for the treatment of HIV/AIDS, as the patents for the drugs are accessible and can 
be used for new fixed-dosage combinations [3], [10]. The manufacturing companies are given the 
flexibility to develop new and appropriate formulations and fixed-dosage combinations to meet the 
specific needs of patients. Often the drugs are not adapted for use in developing countries — as in 
the case of paediatric treatments, as virtually no children are affected by HIV/AIDS in developed 
countries [9]–[11]. 
 
However, certain challenges arise when considering the provision of access to medicine through the 
MPP, such as local manufacturing, distribution, R&D, sub-standard medicines, and other regulatory 
issues [6]. The patents are available to any drug manufacturing companies in low- and middle-
income countries that wish to make use of them; and although the manufacturers need to meet 
certain quality standards, it is often difficult to monitor the quality process of these drugs. Research 
found that, although the MPP does not directly cause any difficulties, the drug manufacturing and 
distribution system in these settings, made possible through the MPP, produces numerous challenges 
[12], [8].  
 
In section 3, the different challenges that arise due to inadequate manufacturing and distribution 
systems in resource-limited settings will be identified through a systematic review, after which they 
will be discussed before developing a challenges landscape. 
3 CHALLENGES POSED BY DRUG MANUFACTURING, DELIVERY, AND RESOURCE-LIMITED 
SETTINGS 
As previously mentioned, the challenges that arise in the manufacturing and distribution of drugs 
for which patents are made available through the MPP can be attributed to inadequate drug 
manufacturing and distribution systems [6], [12]. These challenges affect patient safety, and so 
need to be addressed to ensure that the necessary monitoring systems are in place. The low- and 
middle-income countries that access the MPP also often have limited resources, which further 
complicates the challenges [7]. 
 
In this section, the aim is to identify the challenges arising from drug manufacturing and distribution 
systems in resource-limited settings in developing countries. Once these challenges have been 
identified through a systematic review, a challenges landscape can be developed to indicate the 
system perspective, which will contribute to the development of the requirement specification for 
a PV system in these settings.  
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First the approach to, and the results of, the systematic review will be given, after which the 
different challenges will be defined.  
3.1 Approach 
Due to the great extent of the available literature on drug manufacturing and distribution, a 
systematic review was conducted to limit the review and ensure that a significant amount of 
research into the challenges in this landscape could be included. The academic database Scopus— 
the largest abstract and citation database of peer-reviewed literature 5 — was used to conduct the 
primary search protocol. In addition, since the use of keywords in a search protocol is most effective 
in Scopus, and other databases often deliver irrelevant documents when using this search technique, 
Scopus was deemed a suitable platform for this research inquiry. However, given the focus on 
healthcare environments, databases such as PubMed were used for informal search methods, and 
serendipitous findings were included in the research. Using Scopus, a total of 1870 relevant articles 
were found using specific key words and phrases (Table 1). In order to find the most relevant 
documents, a set of different criteria points were included in the search protocol. These criteria 
points included only documents from 2010 and onwards, as the MPP was only introduced in 2010. 
Furthermore, documents that were not originally published in English but had been translated, and 
any duplicate documents, were excluded. The remaining documents’ titles and abstracts were then 
screened for relevance. Documents concerned with relevant topics, such as the challenges posed by 
drug manufacturing or distribution systems or settings with limited resources regarding HIV/AIDS, 
were included in the final set. In the end, a total of 41 relevant documents were found from Scopus 
and seven from PubMed. These were reviewed and used to identify the challenges that are 
experienced in the context of drug manufacturing and distribution systems in resource-limited 
settings. 
 
The process that was followed to limit the number of documents can be found in Figure 1. 
Table 1: List of search terms used in systematic review 
Index Search terms 
Number of 
articles 
Number after 
2010 
1 Drug Manufacturing 480 257 
2 Drug Manufacturing & Challenges 45 31 
3 Drug Manufacturing & HIV 4 1 
4 Drug Manufacturing & Developing Countries 16 8 
5 Drug Manufacturing & HIV & Challenges 1 1 
6 Drug Manufacturing & Challenges & Developing Countries 3 1 
7 Drug Manufacturing & Quality 188 102 
9 Drug Distributions & Challenges & HIV 232 147 
10 Drug Distributions & Challenges & Developing Countries 14 7 
11 Drug Resistance & HIV & Developing Countries 352 189 
12 Counterfeit drugs & Developing Countries 126 84 
13 Resource Limited Settings & Challenges & HIV 337 257 
14 
Resource Limited Settings & Challenges & developing 
countries 
144 123 
15 Patient safety & HIV & Developing Countries 24 17 
16 Drug Packaging & Challenges & HIV 10 5 
17 Drug Packaging & Challenges & Developing Countries 9 8 
18 Adverse Drug Reactions & Drug Manufacturing 58 29 
19 Adverse Drug Reactions & HIV & Developing countries 84 64 
 
                                                     
5  https://www.elsevier.com/solutions/scopus 
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Figure 1: Process of systematic review 
3.2 Results 
Once the systematic review had been completed, the different challenges posed by inadequate drug 
manufacturing and distribution systems, and the challenges posed by limited resources, could be 
identified and listed. From the literature the following 19 factors were identified: 
 
 Drug dosages 
 Labelling & packaging 
 Specialised drugs 
 Traditional medicines 
 Paediatric drugs 
 Drug resistance 
 Drug quality 
 Counterfeit drugs 
 Substandard drugs 
 Record-keeping 
 Adverse drug reactions (ADR) 
 Drug-drug interactions 
 Drug adherence  
 Drug supply 
 Drug shortages 
 Drug stock-outs 
 Late ART initiation 
 Lack of safety reporting 
 Integrity of system 
Table 2: Overview of occurrences in systematic review 
 
 
From the data provided in Table 2, a number of trends seem to emerge, as some challenges are only 
mentioned in more recent years. For example, labelling, specialised drugs, drug-to-drug 
interactions, and lack of reporting have appeared in the more recent literature, while challenges 
Dosages
Paediatric 
 drugs
Specialised 
 drugs
Traditional 
 medicine
Labelling
Drug 
supply
Drug 
stock-
outs
Drug 
shortages
ADR
Drug 
adherence
Quality
Counterfeit  
 drugs
Drug-drug 
interactions
Substandard 
 drugs
Drug 
resistance
Lack of 
safety 
reporting
Record-
keeping 
Late ART 
Initiation
Integrity 
of system
2010 X X X X X X X X X XX X X
2011 X X X X X X X X X X X X X X X X
2012 X X X X
2013 X X X X X X X X X X X X X 
2014 X X X X X X X X X X X X X X
2015 X X X X X X
2016 X X X X X X X X X X X X
2017 X X X X X X
Total 3 3 3 3 2 4 3 2 13 9 8 4 4 4 3 5 5 4 2
Each X represents a document 
Occurrences of challenges in systematic review
Date
RLSDrug Manufacturing Combination of manufacturing, distribution and RLS
Combination of 
distribution and RLS
1870 articles identified after duplicate 
articles removed. 
Exclude 
 Articles before 2010 
 Articles translated 
 Articles not available as full text 
1187 articles for screening of titles and 
abstracts. 
Exclude articles that are not relevant to: 
 
 Drug manufacturing OR 
 Drug distribution OR 
 Resource-limited setting OR 
 Challenges in HIV settings  
80 articles: introduction, main points, and 
conclusion examined for relevance. 
41 relevant articles found. 
Exclude articles that are not relevant to: 
 
 Drug manufacturing OR 
 Drug distribution OR 
 Resource-limited setting OR 
 Challenges in HIV settings 
48 articles to be examined to determine 
challenges. 
Seven relevant articles retrieved from PubMed using informal 
search methods to be included. 
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such as drug shortages and drug resistance have not appeared in the literature in recent years. From 
Table 2 it can also be seen that certain challenges have occurred more constantly over the last eight 
years, such as ADR and quality challenges.  
3.3 Defining challenges 
The 19 factors that were identified in the systematic review have a specific impact on the 
pharmaceutical and healthcare systems. These challenges are defined and explained in the next 
sub-section. 
3.3.1 Adverse drug reactions  
According to the WHO, an ADR is defined as “any response to a drug which is noxious and unintended, 
and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or 
for the modification of physiological function” [13]. ADRs can affect the treatment process and have 
negative effects on patients’ quality of life, especially for HIV-infected patients on ART. Serious ADR 
often causes patients to stop taking drugs, leading to a lack of drug adherence or to treatment 
failure, which negatively impacts patients and society. ADRs are also often a cause of re-admission 
to a hospital, aggravating the health care burden in resource-limited settings [14]–[19]. It has also 
been shown that ADRs have been found to be preventable, justifying the need to improve 
pharmacovigilance. The early detection of ADRs is also pivotal when ensuring the sustainability and 
optimisation of a treatment process. However, it has been reported that detection, especially in 
paediatric treatments, is difficult [20]. Furthermore, through the MPP, multiple drug manufacturers 
are able to produce generic drugs and new fixed-dosage combinations, making it critical that ADRs 
in HIV patients are monitored carefully [14], [18], [19]. 
3.3.2 Drug adherence 
‘Drug adherence’ refers to patients keeping to the recommendations made for the dosage, timing, 
and frequency of taking their medication. With regard to ART, it is said that 95% drug adherence is 
required to ensure that patients do not develop resistance or suffer from treatment failure [21]. 
From the literature consulted, it has been determined that non-adherence in ART is caused by a 
range of different factors; but one of the main causes is ADR [17], [18], [22]. However, studies in 
developing countries have also indicated that other factors contribute to non-adherence, such as 
dissatisfaction with the healthcare system, perceived stigmas, distance to ART clinics, limited social 
support, poor record-keeping, the attitude of healthcare workers, and certain personal factors [23], 
[17], [21]. Studies do indicate, however, that adherence can be improved with peer counselling and 
education [24].  
3.3.3 Quality 
Ensuring that the drugs that patients take are safe and effective is one of the priorities of the 
pharmaceutical industry, and it needs to be continuously addressed throughout the process. Many 
different aspects, such as good manufacturing practices, quality monitoring, and drug plant 
characteristics contribute to low-quality drugs. It has been found that, in low income countries, the 
quality of drugs is often inconsistent; thus proper quality control should be assessed more often, 
especially when new drug manufacturers are used [25]–[27]. Another aspect to consider when 
addressing drug quality is the production of generic drugs, which is promoted through the MPP. 
Generic drug manufacturing and the production of fixed-dosage combinations challenge the existing 
system, as the different areas of responsibility are misunderstood [28], [23]. 
3.3.4 Lack of reporting 
Limited human resources in developing countries contribute to the lack of reporting of ADRs, 
especially in public HIV healthcare systems. Most low- and middle-income countries have inadequate 
legislation for mandatory reporting by health care professionals [29], [30], [31]. Furthermore, it has 
been found that the severity and preventability of ADRs are often under-reported in developing 
countries, possibly due to inadequate healthcare resources and knowledge among healthcare 
workers in these regions [14]. 
3.3.5 Record-keeping 
Medical health records are essential to health care providers, as they contain specific information 
about a patient, such as their unique patient identifiers and medical history. Medical health records 
contain vital information about a patient’s health, and are needed for their current and future 
treatment. Health care providers are required to write up health records so that the information is 
available when the patient returns to a health care facility [32], [33]. However, it is often the case 
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in developing countries that effective record-keeping is a challenge [31], [34]. Healthcare providers 
mention that patients’ records are often lost, resulting in the loss of all previous data, and 
sometimes even leading to certain medical procedures being repeated [21]. This therefore underpins 
the need for effective record-keeping systems, such as electronic health records.  
3.3.6 Counterfeit drugs 
The WHO describes counterfeit or falsified drugs as “medical products that deliberately/ 
fraudulently misrepresent their identity, composition or source” [35]. The WHO also states that 
counterfeit drugs can be branded or generic drugs that contain the incorrect ingredients, or none at 
all, or inadequate amounts of active ingredients, or that are falsely packaged [36]. The health of 
patients who receive counterfeit drugs is threatened, as they are at risk of developing ADR or drug 
resistance [23], [27], [28], [37]. Counterfeit drugs are often a concern in areas where there is a 
shortage of drugs, or drug manufacturing and distribution systems are not registered [23], [38].  
3.3.7 Drug-drug Interactions 
The interaction between ARVs and other drugs is often harmful to a patient’s treatment procedure. 
ARVs are often co-administered with antitubercular medication; however, this often leads to a 
higher frequency of drug-induced liver incidents and peripheral neuropathy. Thus TB/HIV co-
infected patients’ treatment should be managed more carefully. ‘Drug-drug interaction’ is defined 
as a change in the effect of the drug when it is taken together with another drug, and it can often 
lead to ADR [39]. The use of traditional medicines has also given rise to challenges in drug-drug 
interactions [23]. 
3.3.8 Drug supply 
In developing countries, drug supply has often been a concern, especially for illnesses such as TB 
and HIV/AIDS, whose treatment requires a strict regime to be effective. Furthermore, when limited 
amounts of ART are available, ethical issues often arise about how the medication should be 
prioritised for different patients [23]. Delays in drug delivery in resource-limited settings are often 
caused by poor infrastructure such as poor roads and by financial burdens such as a lack of funding 
for fuel [37], [40]. The challenges posed by poor drug supply involve all aspects of the supply chain, 
from ordering systems to the storage and distribution of drugs. Case studies on weak ARV supplies 
in South Africa found that they were often caused by poor communication between provincial 
districts and facilities or between the consumer and the facilities. Studies have shown that supply 
systems that rely on consumer ordering affect shortages [41].  
3.3.9 Late ART initiation 
From the literature it has become evident that the need to ensure that people start their treatment 
during the early phases of the disease is just as important as ensuring that patients receive treatment 
[42]. Although there is no clear definition of just when it is ‘late’ for a patient to start ART, it can 
be deduced that it is when a patient’s CD4 count is very low (CD4 <50 cells/μL). Patients who initiate 
late ART have a higher risk of opportunistic infections than patients who start treatment at a higher 
CD4 count, with TB being the most common illness [43], [44]. From previous studies, the causes of 
late ART initiation can be grouped into health system-related issues, socio-economic obstacles, or 
inappropriate treatment criteria [44].  
3.3.10 Substandard drugs 
The WHO defines substandard drugs as “authorized medical products that fail to meet either their 
quality standards or specifications, or both” [35]. A drug is thus regarded as a substandard drug if it 
contains too many or too few active ingredients in comparison with the formulation specifications. 
However, there have been substandard drugs that were toxic in nature or that contained fatal levels 
of toxic ingredients. Substandard drugs are often found in poorer settings with manufacturing and 
distribution systems that use unqualified personnel and inadequate control systems. Substandard 
drugs are more frequently found, and pose a greater threat to patients than counterfeit drugs [27], 
[36]. 
3.3.11 Dosages 
Taking the correct dosage when on ART is important, since taking an incorrect dosage leads to there 
being an inadequate amount of the drugs to fight the virus. Often, when tablets are split, asymmetry 
results in an unproportioned dosage of the ARV drugs. Furthermore, it cannot be assumed that the 
ingredients are evenly distributed in a tablet; thus pill splitting is not recommended [45].  
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3.3.12 Drug resistance 
Drug resistance is when the response to a drug in a susceptible parasite population decreases 
significantly [46]. According to studies by the WHO, it was found that in 2010 the prevalence of HIV 
drug resistance for patients starting treatment was 6.8% for any drug, and that the treatment of 
these patients was more likely to fail [47], [48]. Drug resistance leads to further challenges relating 
not only to the patient’s own future treatment, but also to the whole community [25].  
3.3.13 Drug stock-outs 
The WHO defines a drug stock-out as the total absence of a medication that has been identified as 
essential at the point of service delivery [49]. Drug stock-outs are often the result of poor 
infrastructure and insufficient human resources [40], [50]. Although alternative ARTs are often 
provided in the case of a stock-out, it still poses the threat of drug resistance, as it might cause 
suboptimal drug levels [34]. It has been reported that one-third of countries worldwide struggle with 
drug stock-outs, thus increasing the risk of treatment failure and failed drug adherence [30], [34], 
[51]. To ensure that stock-outs do not occur, it is critical that ART programme planning and rational 
forecasting processes are in place [30]. 
3.3.14 Paediatric drugs 
The need for paediatric antiretroviral drugs is much higher in low- to middle-income countries, as 
developed countries have significantly reduced the mother-to-infant HIV rate. Furthermore, the use 
of adult ART for children is seen as ineffective, as children absorb and metabolise drugs differently 
than do adults. Through the MPP, drug manufacturers in developing countries can develop innovative 
fixed-dosage combinations specifically for paediatric use. However, when developing paediatric 
drugs, the palatability, taste, size, dosages, formulation, and ease of handling or administration of 
the drugs should be considered [45], [52].  
3.3.15 Specialised drugs 
In developing countries, certain specialised drugs are manufactured to specific contextual criteria. 
Two examples of such drugs that occur in the HIV treatment context are paediatric antiretrovirals 
and the use of traditional medicines. This is often the case in countries that are part of the MPP, as 
the patents often only cater for  a developed country’s needs [53], [45]. 
3.3.16 Traditional medicines 
Many cultural and social differences that further complicate HIV/AIDS treatment in developing 
countries need to be considered, one being the increasing production and use of traditional 
medicines [54]. The increased production of these medicines raises issues of quality control, 
although intercultural standards are being developed for traditional medicines. Aspects to consider 
in relation to quality control are the use of raw materials, the knowledge of the manufacturers, and 
the lack of general safety studies [55]–[57].  
3.3.17 Drug shortages 
A drug shortage is defined by the WHO as the insufficient supply of medication or health products 
to meet the public’s and patients’ needs [49]. The drugs that are often affected by shortages are 
produced by smaller generic companies with little redundant capacity, which complicates the 
situation with production problems [58]. Previous case studies showed that patients who were on a 
waiting list for ART often died due to drug shortages. However, drug shortages can be prevented if 
there are sufficient resources to inspect and approve new drugs and ensure the quality of drugs. It 
has also been predicted that reducing the number of reviews and speeding up inspections would 
help to avoid shortages [59].  
3.3.18 Integrity of system 
The support, integrity, and confidentiality of health care workers has been seen to have an impact 
on ART. From the literature it has been found that HIV patients’ distrust of and dissatisfaction with 
the healthcare system can lead to serious problems such as late treatment initiation or poor drug 
adherence, which often result in drug resistance or treatment failure. Healthcare workers who are 
supportive will motivate patients to take their ARVs, and educate them about the consequences and 
benefits of keeping to the treatment programme [21], [44],[60]. A case study [44] revealed that HIV 
patients often do not seek treatment, as they know that the healthcare staff often discuss their 
status — which is a very sensitive topic — in public. The compassion and support of healthcare 
workers are important in ensuring that patients follow through with their treatment [25]. 
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3.3.19 Labelling 
Mislabelling drugs can have a severe impact on a patient’s safety, and can be more harmful for 
them. According to the WHO, labelling on drugs needs to contain the names and amount of the 
active ingredients, the batch number from the manufacturer, the expiry date, the name and address 
of the manufacturer, any storage instructions, and directions for use. It is particularly important 
that the directions and guidelines for use are clearly indicated [61].  
4 CHALLENGES LANDSCAPE 
As previously mentioned, the challenges that were identified in section 3 were found to relate to 
one another and to have an impact on one another. It was also established that challenges could 
have (possibly different) impacts on the various parts of the pharmaceutical value chain. Thus, an 
overview of the ‘challenges landscape’ is developed here to gain a holistic view of the challenges 
that face the drug manufacturing and distribution systems in relation to the provision of drug patents 
through the MPP. The challenges landscape will serve as a guide to determining any shortcomings in 
the traditional PV system by developing a requirement specification for a (niche) PV system that will 
support effective and efficient drug surveillance and monitoring. However, the development of the 
requirement specification falls outside of the scope of this paper; the key focus of this paper is, as 
mentioned earlier, to develop a challenges landscape to understand the system perspective in these 
settings.  
 
The pharmaceutical value chain framework used for the purpose of this study has four sections: 
supply, distribution, product, and health system [62]. The ‘supply’ section is then sub-divided into 
‘drug development’ and ‘manufacturing’, while the ‘health system’ section is split into ‘patient 
usage’ and ‘monitoring systems’ [62].  
 
The challenges landscape, as discussed in the sections that follow, is discussed from three 
perspectives: firstly, the relationships between the various challenges are considered and presented 
in a relationship diagram; secondly, the relationship diagram, the pharmaceutical value chain 
framework, and the various challenges are amalgamated and presented in a schematic 
representation of the challenges landscape; and thirdly, the linkages and groupings presented in the 
schematic representation of the challenges landscape are elaborated on. 
4.1 Relationship diagram & schematic representation of the challenges landscape 
In Figure 2 the respective relationships between the challenges are indicated. These relationships 
were not necessarily explicitly mentioned in the literature, but after synthesising the information 
gathered through the systematic literature review, certain correlations and relationships between 
the different challenges could be identified. The relationships indicated in Figure 2 are grouped so 
as to indicate the impact a relationship has on a specific section of the pharmaceutical value chain. 
These sections of the value chain are distinguished in the key provided in Figure 2. In the case where 
a relationship has an impact on more than one section, both are indicated. The relationship diagram 
was used as an aid to create the challenges landscape. Schematic representation of the challenges 
landscape 
 
Using the relationship diagram in section 4.1 and the information from section 3, a challenges 
landscape (Figure 3) was developed to indicate the inter-relationships and impacts between the 
different challenges, and their relationships with the different stages of the pharmaceutical value 
chain.  
 
As seen in the schematic representation, the pharmaceutical chain is subdivided into four sections: 
supply, distribution, product, and health system. The challenges are in three main groups, referred 
to as A1-A3. They are formed when considering the systematic review and the causes of the 
challenges — namely, drug manufacturing and distribution in resource-limited settings. A1 refers to 
challenges due to inadequate manufacturing and distribution systems; A2 to challenges due to 
quality issues in drug manufacturing and distribution; and A3 to challenges due to limited resources. 
These challenges are grouped in subsections within these main groups; these sub-groupings, C1–C8, 
are discussed in section 4.2. 
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Figure 2: Relationship diagram (see online version for colour) 
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Figure 3: Challenges landscape (see online version for colour) 
4.2 Links and groupings  
As mentioned earlier, the different challenges have certain correlations, impacts, and/or 
relationships on or with each other, either directly or indirectly, which are illustrated by the 
challenges landscape in section 4.1. The explanation of the different groupings and relationships in 
the challenges landscape is provided in Table 3. It should be noted that the groupings and links 
between the different challenges were created with reference to the literature that was found 
through the systematic review and provided in section 3.  
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Table 3: Explanation of groupings of different challenges  
Code Value Chain Grouping Explanation 
C1 
Drug 
development 
and 
manufacturing 
Specialised drugs, 
paediatric drugs, 
traditional 
medicines 
In low- and middle-income countries, the development and manufacturing 
of drugs often requires the creation of drugs for specific needs of patients, 
referred to as ‘specialised’ drugs. In the case of HIV, the two specialised 
drugs that are most often found are paediatric drugs and traditional 
medicines [53], [45]. These challenges mostly appear in the phases of drug 
development and manufacturing. Furthermore, it is seen that traditional 
medicines often have an impact on drug-drug interactions [23]. 
C2 
Drug 
development 
and 
manufacturing 
Quality, dosages, 
labelling 
The identified quality challenges have been shown to have an impact on 
the supply side of the value chain. Drug manufacturing companies have to 
have quality systems in place to ensure that the drugs they manufacture 
are safe and effective, and will not harm patients [26], [27]. Inadequate 
quality systems in drug manufacturing companies further complicate 
challenges such as drug dosage and labelling. If drug manufacturing 
companies do not have quality systems in place, the drugs dosages are 
often not adequate, as the ingredients are not distributed evenly [45]. The 
labels are often also incorrect. These challenges cause further problems 
with patient safety [61].  
C3 Distribution 
Drug supply, drug 
shortages, drug 
stock-outs 
In the drug distribution part of the value chain, drug supply in low- and 
middle-income countries is one of the major concerns that is further 
affected by limited resources in these settings. As mentioned, many 
factors affect drug supply, from poor infrastructure to factors in the supply 
chain such as ordering systems [41]. The problems in drug supply create 
difficulties such as drug shortages and drug stock-outs. These lead to 
problems with patient safety, since shortages and stock-outs often are the 
causes of drug resistance in patients and poor adherence [34]. 
C4 
Product, 
patient usage 
Drug-drug 
interactions, ADR, 
drug adherence 
Of the challenges that were identified, drug-drug interaction is one that 
arises in the final product stage of the value chain. As mentioned, ARVs 
often have to be taken in combination with other drugs, which can lead to 
negative drug-drug interactions. It has also been found that traditional 
medicines, which are often used in low- and middle-income countries, 
have an effect on drug-drug interactions [23]. Drug-drug interactions often 
also cause serious side effects and ADRs [39]. As previously mentioned, 
ADRs often have an effect on a patient’s treatment process, as serious 
ADRs can impact a patient’s adherence to the treatment, since they often 
stop taking their medications due to ADRs [21]. This inevitably affects not 
just the patient but the community as a whole. Drug adherence implicates 
the value chain in both the final product stage and the patient usage 
stage.  
C5 Product 
Quality, 
counterfeit drugs, 
sub-standard 
drugs 
The quality of the final product is reduced by ineffective manufacturing 
and distributions systems [27], [28]. Drugs of inauspicious quality often 
lead to counterfeit drugs or sub-standard drugs. These challenges are 
mostly caused by a lack of quality in the drug supply process, and can 
seriously affects patient safety. Furthermore, counterfeit drugs often lead 
to serious ADR or drug resistance [23], [27], [28], [37].   
C6 Patient usage Drug resistance 
Drug resistance is one of the challenges in the HIV setting that is 
associated with patient usage. Although drug resistance is not grouped 
together with other challenges, many factors impact on and lead to drug 
resistance. From the identified challenges, the biggest contributors to drug 
resistance are drug delivery, shortages, stock-outs, and poor drug 
adherence [34], [42]. Furthermore, drug resistance is complicated by 
inadequate drug monitoring systems, such as the low integrity of a health 
system and poor record-keeping [21], [44].    
C7 Monitoring 
Integrity of the 
health system, 
record-keeping 
system, late ART 
initiation 
In monitoring — the final stage of the drug value chain — many challenges 
arise from limited resources. The poor integrity of the health care system 
and the lack of effective record-keeping are two of the contributing 
factors for late ART initiation. Late ART initiation can be very detrimental 
to patient care, and often leads to unnecessary deaths. Furthermore, the 
lack of effective record-keeping and dissatisfaction with the health care 
system affects drug adherence, which again leads to drug resistance [44].  
C8 Monitoring Lack of reporting 
The lack of reporting during ART is one of the major challenges in 
resource-limited settings during the monitoring stage of the value chain. As 
mentioned, preventable ADRs have often been found to be under-reported, 
leading to further complications such as poor drug adherence and drug 
resistance [14].  
4.3 The need to investigate the development of a niche PV system 
Given the challenges landscape discussed above, the three perspectives — the relationships between 
the various challenges, the schematic representation of the challenges landscape, and the discussion 
on the linkages and groupings — lead to a comprehensive understanding of and insight into the 
challenges that arise from drug manufacturing and distribution systems that are related to the MPP 
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in settings with limited resources. From this challenges landscape, it is evident that there are 
shortcomings in the current (traditional) PV systems, as the challenges faced in these settings are 
not considered or incorporated when developing and designing the requirements and characteristics 
of a traditional PV system [63].  
 
Thus, the challenges landscape highlights the need for an innovative PV system, such as a niche PV 
system, not only to support, facilitate, and improve the manufacturing and distribution of drugs and 
to address the challenges faced in these settings, but also to ensure that such a PV system will not 
create any additional problems or reinforce existing ones. The insights gained from the challenges 
landscape will assist with the development of a requirement specification for such a niche PV system 
that will address the current shortcomings in drug surveillance and monitoring in these settings. 
5 CONCLUSION AND FURTHER RESEARCH 
The challenges that arise in the manufacturing and distribution systems of drugs whose patents are 
made available through the MPP were discussed in this article. The challenges specifically related 
to developing countries, and challenges faced within the HIV/AIDS setting, were considered. It was 
determined that these challenges complicate different stages of the pharmaceutical value chain, 
and thus an innovative PV system is required to address these challenges.  
 
The challenges landscape developed in this paper is a useful tool that indicates the relationships 
from a system perspective. Furthermore, the challenges landscape and the insights gained from it 
can be used in combination with other elements that relate to drug surveillance monitoring, such as 
best practices and current PV characteristics, to develop a requirement specification for an effective 
PV system in these settings.  
 
In conclusion, this paper highlights the need for an innovative PV system, such as a niche PV system 
for a specific region and specific drug, to address and possibly eliminate the challenges that are 
faced in these settings, and to increase the effectiveness and efficiencies of such systems, given 
their unique characteristics. The insights gained from this paper will be considered when designing 
a niche PV system by transforming or transitioning from the traditional PV system. 
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